Symbol Lookup

Friday March 24, 2017 3:55 PM ET. Data delayed 15 minutes.
5.52
0.04 (0.73%)
Bid/Lots
5.52/1
Ask/Lots
5.55/1
Open/Prev Close
5.49/5.48
Day Range
5.32-5.59
52-Week Range
5.20-13.68
Vol/Avg Daily Vol
24.7K/86.8K
  • TSX Comp
  • TSX Venture
  • DJIA
  • S&P 500
  • NASDAQ
Price Comparison Chart
Data delayed at least 15 minutes.

Recent News»

0 New Today
European ADRs Edge Lower as Manufacturers Head South
1 hour ago by MT Newswires
10:44 AM EDT, 03/24/2017 (MT Newswires) -- American depository receipts of European stocks were 0.1% lower at 126.68 on the Bank of New York Mellon Europe ADR Index on Friday morning. Decliners in Continental Europe were led by Marine Harvest (M...
European ADRs Fractionally Higher as Health Care Stocks See Mixed Fortunes
10:27AM ET on Monday Mar 20, 2017 by MT Newswires
10:27 AM EDT, 03/20/2017 (MT Newswires) -- American depository receipts of European stocks were 0.1% higher at 127.36 on the Bank of New York Mellon Europe ADR Index on Monday morning. Gainers in Continental Europe were led by Cellectis (CLLS), ...
European ADRs Edge Higher as Banks See Mixed Fortunes
10:46AM ET on Friday Mar 17, 2017 by MT Newswires
10:46 AM EDT, 03/17/2017 (MT Newswires) -- American depository receipts of European stocks were 0.3% higher at 127.51 on the Bank of New York Mellon Europe ADR Index on Friday morning. Gainers in Continental Europe were led by Telefonica (TEF), ...
BRIEF-Lapides Asset Management LLC reports 5.1 pct passive stake in Trinity Biotech
11:33AM ET on Wednesday Mar 15, 2017 by Thomson Reuters

March 15 (Reuters) - Trinity Biotech Plc

* Lapides Asset Management LLC reports 5.1 percent passive stake in trinity Biotech Plc as of March 6 - sec fi...

Trinity Biotech Q4 Results Weaker Than Same Period Last Year
10:13AM ET on Tuesday Mar 14, 2017 by MT Newswires
10:13 AM EDT, 03/14/2017 (MT Newswires) -- Trinity Biotech (TRIB) said Tuesday its Q4 earnings per share was $0.04 compared with $0.11 in the same period a year ago. The company said revenue was $23.7 million, compared with $24.9 million in the s...

Company Information

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine. It operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business. Trinity Biotech's blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections.

CONTACT INFORMATION

HeadquartersIDA Business Park
BRAY, Ireland 18
Phone--
Fax--

EXECUTIVE OFFICERS

Executive Chairman of the BoardRonan O'Caoimh
Chief Financial Officer, SecretaryKevin Tansley
Chief Operating Officer, Executive DirectorRory Nealon
Chief Scientific Officer, and Vice President CardiacEric Brouwer
Executive DirectorJames Walsh

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Stocks Ratings Sample

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

  •  
  • INK Company Insider

    Detailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®

  • S&P Capital IQ Stock Report

    S&P Capital IQ's analysts' overview and valuation, with key fundamental, quantitative, and technical analysis.

  • TDSI Morning Action Notes

    Morning Institutional Report of company updates and new recommendations.

Market Cap$131.3MBeta1.17
Revenue (TTM)$100.9MEPS$0.07
Shares Out.24.0MBook Value$8.93
Dividend Yield0.00%P/E74.5x
Annual Dividend Rate0.00 USDPrice/Sales (TTM)1.3
Ex-Div Date1/1/01P/Cash Flow (TTM)--
Pay Date1/1/01Operating Margin9.94%

*GAAP = prior to non-GAAP analyst adjusted earnings.

(Non-GAAP)*

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Stocks Calendar Sample